First, through analysis of the public HCC dataset from the TCGA and GEO databases, we observed that patients with high CXCL2 expression exhibited a higher immunophenoscore (IPS), which indicated enhanced suitability for immunotherapy, and were more prone to benefit from anti‐PD‐1 treatment (Figure6A; Figure S9A, Supporting Information). Here, CXCL2 is linked to hepatocellular carcinoma.